Aducanumab Lowers Amyloid Plaque Associated with Alzheimer’s, Extension Trial Shows

Aducanumab Lowers Amyloid Plaque Associated with Alzheimer’s, Extension Trial Shows
Aducanumab reduced deposits of the amyloid plaque associated with Alzheimer’s disease in the brains of early-stage patients who took part in a three-year extension trial, Biogen reports. After the study ended, deposits of the protein were lower in many patients’ brains than the level that a scan would identify as constituting Alzheimer’s, researchers said. The treatment

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *